Twist Bioscience Corporation(TWST) Stock Research - Grey Stern Research
Loading...

Twist Bioscience Corporation (TWST) Stock Analysis

$47.01 (1.10%)

TWST Financial Performance


Use the table below to view Twist Bioscience Corporation's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $46.50 -
52 Week Low $12.62 -
52 Week High $50.50 -
Market Cap $2.7 Billion 12/16
Gross Margin 41% 11/16
Profit Margin -60% 13/16
EBITDA margin -54% 13/16
Q2 - 2024 Revenue $75.3 Million 13/16
Q2 - 2024 Earnings -$45.5 Million 11/16
Q2 - 2024 Free Cash Flow -$20.0 Million 12/16
Trailing 4 Quarters Revenue $277.5 Million 13/16
Trailing 4 Quarters Earnings -$192.1 Million 11/16
Quarterly Earnings Growth 23% 6/16
Annual Earnings Growth -4% 11/16
Quarterly Revenue Growth 25% 3/16
Annual Revenue Growth 24% 3/16
Cash On Hand $243.3 Million 11/16
Short Term Debt $14.6 Million 11/16
Long Term Debt $74.8 Million 13/16

Twist Bioscience Corporation Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Twist Bioscience Corporation's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 8/16
PS 9.76 2/16
PB 4.83 7/16
PC 11.13 11/16
Liabilities to Equity 0.25 13/16
ROA -0.27 11/16
ROE -0.34 11/16
Current Ratio 4.92 2/16
Quick Ratio 2.06 2/16
Long Term Debt to Equity 0.13 12/16
Debt to Equity 0.16 12/16
Burn Rate 4.67 10/16
Cash to Cap 0.09 6/16
CCR 0.44 11/16
EV to EBITDA -62.91 14/16
EV to Revenue 9.20 3/16

Company Details

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.

CEO: Ms. Emily Leproust

Website: https://www.twistbioscience.com

Address: 681 GATEWAY BLVD. South San Francisco, CALIFORNIA

Exchange: NASDAQ Global Select

Industry: Diagnostics & Research

Twist Bioscience Corporation Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Twist Bioscience Corporation. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
CareDx, Inc CDNA $807.3 Million
Agilent Technologies, Inc. A $45.2 Billion
Danaher Corporation DHR $196.9 Billion
Thermo Fisher Scientific Inc. TMO $227.2 Billion
Illumina, Inc. ILMN $17.7 Billion
Exact Sciences Corporation EXAS $9.3 Billion
IQVIA Holdings Inc. IQV $42.1 Billion
Waters Corporation WAT $21.1 Billion
Mettler-Toledo International Inc. MTD $32.5 Billion
ICON Public Limited Company ICLR $26.0 Billion
Invitae Corporation NVTA $5.4 Million
Natera, Inc. NTRA $13.1 Billion
Castle Biosciences, Inc. CSTL $669.2 Million
Guardant Health, Inc. GH $3.1 Billion
Personalis, Inc. PSNL $72.7 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
TWST Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 75.3 Million -$45.5 Million
Q1 2024 $ 71.5 Million -$43.0 Million
Q4 2023 $ 66.9 Million -$46.2 Million
Q3 2023 $ 63.7 Million -$57.4 Million
Q2 2023 $ 60.2 Million -$59.2 Million
Q1 2023 $ 54.2 Million -$41.8 Million
Q4 2022 $ 57.3 Million -$51.1 Million
Q3 2022 $ 56.1 Million -$60.5 Million

View All

TWST Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $243.3 Million $702.8 Million $89.4 Million $560.1 Million
Q1 2024 $266.3 Million $732.8 Million $91.9 Million $590.0 Million
Q4 2023 $286.5 Million $776.4 Million $94.1 Million $623.4 Million
Q3 2023 $307.5 Million $810.3 Million $93.0 Million $657.6 Million
Q2 2023 $315.2 Million $853.9 Million $91.2 Million $703.9 Million
Q1 2023 $316.7 Million $910.0 Million $94.0 Million $746.3 Million
Q4 2022 $378.7 Million $961.4 Million $94.9 Million $789.4 Million
Q3 2022 $376.2 Million $979.7 Million $78.6 Million $820.7 Million

View All

TWST Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 -$20.0 Million -$603,000 -$22.9 Million
Q1 2024 -$24.5 Million -$1.5 Million -$20.2 Million
Q4 2023 -$24,000 $0 -$24,000
Q3 2023 -$27.9 Million -$4.5 Million -$5.7 Million
Q2 2023 -$53.3 Million -$9.1 Million -$1.5 Million
Q1 2023 -$65.9 Million -$11.8 Million -$61.2 Million
Q4 2022 -$17.7 Million -$16.5 Million $2.4 Million
Q3 2022 $10.7 Million $44.8 Million -$31.4 Million

View All